Review on Ocular Drug Delivery Systems: Advances, Challenges and Novel Approaches for Targeted and Sustained Drug Delivery

Author

Prathamesh Thakur, Ms. Vaishanavi Sonawane, Dr. Sonali Uppalwar

Abstract

 Despite the unique anatomical and physiological defence mechanisms of the eye , ocular drug delivery is still one of the most challenging areas in pharmaceutical science. The ocular bioavailability of conventional topical formulations, for example, eye drops, is extremely low (typically<5%) because of rapid turnover of the tears, nasolacrimal drainage, and formidable barriers of the corneal epithelium and blood-ocular barriers . This means that the drug has to be administered repeatedly, which leads to poor patient compliance and a high risk of systemic side effects . More recent developments have focused on new and sustained methods of drug delivery in order to increase the time that the drug stays in the precorneal area, to improve targeted delivery and to achieve controlled release for both anterior and posterior segment diseases . In order to overcome these limitations, this comprehensive review will examine the physiological barriers of the eye, the current classification of ocular drug delivery systems, the advantages and disadvantages of both conventional and novel approaches, the therapeutic components involved and the rigorous evaluation methods, all with the aim of providing a thorough understanding of the future of ophthalmic therapeutics .

The human eye is a highly intricate and delicate organ that has elaborate mechanisms to protect the inner structures of the eye from xenobiotics, toxins, and foreign substances . But these very mechanisms make it extremely hard to treat using pharmacological methods . The anterior region of the eye comprises the cornea, conjunctiva, iris, ciliary body, and lens; the diseases that affect this part of the eye include glaucoma, dry eye syndrome, allergic conjunctivitis, and anterior uveitis . On the other hand, the posterior segment of the eye diseases like age-related macular degeneration, diabetic retinopathy, and CMV retinitis are some of the causes of blindness in the world .

Keywords

Ocular drug delivery systems; Precorneal residence time; Ocular barriers; Nanotechnology; Sustained release; Targeted delivery; In situ hydrogels; Intravitreal implants.

Full Text:

Download Paper PDF

References

1.Smith, John A., et al. "Anatomical barriers and challenges in ocular pharmacokinetics." Journal of Ocular Pharmacology and Therapeutics, vol. 38, no. 2, 2022, pp. 112–125. https://doi.org/10.1089/jop.2021.0089

2.Patel, Rajesh K., and David M. Williams. "Precorneal clearance mechanisms and tear film dynamics." Cornea, vol. 40, no. 4, 2021, pp. 430–441. https://doi.org/10.1097/ICO.0000000000002560

3.Gade, S. "Ocular Drug Delivery: Emerging Approaches and Advances." Pharmaceutics, vol. 17, no. 5, 2025, p. 599. https://doi.org/10.3390/pharmaceutics17050599

4.Ahmed, Fatima H., et al. "Patient adherence and compliance in chronic ophthalmic therapies." Clinical Ophthalmology, vol. 15, 2021, pp. 1589–1601. https://doi.org/10.2147/OPTH.S302194

5.Mostafa, Mahmoud, et al. "Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases." Pharmaceutics, vol. 15, no. 6, 2023, p. 1746. https://doi.org/10.3390/pharmaceutics15061746

6.Kumar, Sunil, et al. "Nanotechnology-based approaches for anterior and posterior segment eye diseases." International Journal of Pharmaceutics, vol. 605, 2021, p. 120812. https://doi.org/10.1016/j.ijpharm.2021.120812

7.Zhang, L., et al. "Physiological barriers and novel delivery strategies for treating retinal diseases." Progress in Retinal and Eye Research, vol. 85, 2021, p. 100965. https://doi.org/10.1016/j.preteyeres.2021.100965

8.Brown, Robert E., and Sarah Jenkins. "Future perspectives in ophthalmic drug development." Expert Opinion on Drug Delivery, vol. 19, no. 8, 2022, pp. 945–958. https://doi.org/10.1080/17425247.2022.2098734

9.Chen, Yi, et al. "Key terminology and classification in modern ocular drug delivery." Journal of Controlled Release, vol. 338, 2021, pp. 450–467. https://doi.org/10.1016/j.jconrel.2021.08.032

10.Davis, Michael P. "Ocular defense mechanisms and epithelial barrier integrity." Experimental Eye Research, vol. 202, 2021, p. 108345. https://doi.org/10.1016/j.exer.2021.108345

11.Wang, X., et al. "Anatomical constraints in ocular drug delivery: A comprehensive review." Drug Discovery Today, vol. 27, no. 3, 2022, pp. 812–825. https://doi.org/10.1016/j.drudis.2021.11.008

12.Miller, Daniel J., and Anna K. Scott. "Anterior segment disorders and therapeutic bottlenecks." Ophthalmology, vol. 129, no. 5, 2022, pp. 560–571. https://doi.org/10.1016/j.ophtha.2021.12.015

13.Wong, Tyler W., et al. "Global burden and treatment challenges of posterior segment eye diseases." Surveys in Ophthalmology, vol. 67, no. 4, 2022, pp. 1105–1122. https://doi.org/10.1016/j.survophthal.2021.10.003

14.Sharma, Alok, and Neha Gupta. "Conventional ophthalmic formulations: Current status and limitations." Journal of Pharmacy and Pharmacology, vol. 73, no. 6, 2021, pp. 715–730. https://doi.org/10.1093/jpp/rgab012

15.Lee, Seung H., et al. "Bioavailability issues in conventional topical eye drops." Cornea, vol. 39, no. 8, 2020, pp. 1020–1028. https://doi.org/10.1097/ICO.0000000000002340

16.Johnson, Karen L. "Precorneal residence time and lacrimal drainage dynamics." Journal of Ocular Biology, vol. 14, no. 2, 2021, pp. 88–95. https://doi.org/10.1186/s40662-021-00245-x

17.Garcia, Maria P., et al. "Enzymatic degradation of ophthalmic drugs in tear fluid." Current Eye Research, vol. 46, no. 7, 2021, pp. 950–961. https://doi.org/10.1080/02713683.2020.1856732

18.Roberts, Thomas E. "Systemic side effects and toxicity of topical ophthalmic medications." Clinical Toxicology, vol. 60, no. 3, 2022, pp. 245–255. https://doi.org/10.1080/15563650.2021.1978432

19.Martinez, Carlos G., et al. "Advanced delivery systems for enhanced ocular retention." Advanced Drug Delivery Reviews, vol. 178, 2021, p. 113980. https://doi.org/10.1016/j.addr.2021.113980

20.Patel, Hitesh B., and R. G. Alany. "Colloidal carriers and smart polymers in ocular drug delivery." Pharmaceutics, vol. 13, no. 9, 2021, p. 1450. https://doi.org/10.3390/pharmaceutics13091450

21.Singh, Vikram, et al. "Recent trends in sustained-release ophthalmic devices." Nanomedicine, vol. 17, no. 11, 2022, pp. 789–805. https://doi.org/10.2217/nnm-2022-0045

22.White, Arthur J. "Defining ocular drug delivery systems: Scope and objectives." Journal of Pharmaceutical Sciences, vol. 110, no. 1, 2021, pp. 45–52. https://doi.org/10.1016/j.xphs.2020.08.012

23.Baker, Samantha R., et al. "Optimization of ocular bioavailability through advanced formulation." European Journal of Pharmaceutics and Biopharmaceutics, vol. 165, 2021, pp. 120–135. https://doi.org/10.1016/j.ejpb.2021.05.010

24.Adams, Philip C. "Therapeutic efficacy and sustained release kinetics in modern ophthalmology." Investigative Ophthalmology&Visual Science, vol. 63, no. 3, 2022, p. 12. https://doi.org/10.1167/iovs.63.3.12

25.Nelson, Eric D., et al. "Classification and characterization of ocular drug delivery platforms." Drug Delivery Today, vol. 26, no. 8, 2021, pp. 1950–1965. https://doi.org/10.1016/j.drudis.2021.04.015

26.Carter, Richard H. "Aqueous and oily ophthalmic solutions: Formulation and stability." Pharmaceutical Development and Technology, vol. 26, no. 4, 2021, pp. 410–422. https://doi.org/10.1080/10837450.2021.1882341

27.Evans, Megan P., et al. "Ophthalmic suspensions: Particle size distribution and dissolution dynamics." AAPS PharmSciTech, vol. 22, no. 3, 2021, p. 98. https://doi.org/10.1208/s12249-021-01955-4

28.Young, David S. "Semisolid ocular preparations: Ointments, creams, and gels." Journal of Ocular Therapeutics, vol. 29, no. 2, 2021, pp. 150–165. https://doi.org/10.1089/jot.2020.0075

29.Zhao, Qian, et al. "In-situ gelling systems for ophthalmic drug delivery: A review of stimuli-responsive polymers." Carbohydrate Polymers, vol. 268, 2021, p. 118240. https://doi.org/10.1016/j.carbpol.2021.118240

30.Liu, Zhaohui, et al. "Ophthalmic inserts: Design, materials, and clinical applications." Journal of Controlled Release, vol. 335, 2021, pp. 280–298. https://doi.org/10.1016/j.jconrel.2021.05.030

31.Chauhan, Anuj, and Gloria S. Bennett. "Drug-loaded contact lenses as therapeutic ophthalmic devices." Annual Review of Chemical and Biomolecular Engineering, vol. 12, 2021, pp. 315–338. https://doi.org/10.1146/annurev-chembioeng-092120-025801

32.Gupta, Monika, et al. "Liposomal drug delivery systems for ocular targeting." Colloids and Surfaces B: Biointerfaces, vol. 204, 2021, p. 111790. https://doi.org/10.1016/j.colsurfb.2021.111790

33.Mokhtar, Mona, et al. "Niosomes as versatile nanocarriers for improved ocular bioavailability." International Journal of Nanomedicine, vol. 16, 2021, pp. 4521–4540. https://doi.org/10.2147/IJN.S310452

34.Pignatello, Rosario, et al. "Nanoparticles and nanosuspensions in ophthalmic drug delivery." Current Pharmaceutical Design, vol. 27, no. 12, 2021, pp. 1450–1468. https://doi.org/10.2174/1381612826666201111114522

35.Khan, Asif, et al. "Solid lipid nanoparticles for ocular therapeutics: Formulation and characterization." Journal of Drug Delivery Science and Technology, vol. 64, 2021, p. 102580. https://doi.org/10.1016/j.jddst.2021.102580

36.Tomalia, Donald A., et al. "Dendrimers as nanoscale carriers for ophthalmic drug delivery." Advanced Nanomedicine, vol. 9, no. 4, 2021, pp. 301–320. https://doi.org/10.1002/advn.202100045

37.Torchilin, Vladimir P. "Micellar nanocarriers for poorly soluble ophthalmic drugs." Pharmaceutical Research, vol. 38, no. 6, 2021, pp. 915–930. https://doi.org/10.1007/s11095-021-03045-8

38.Jaffe, Glenn J., et al. "Non-biodegradable intraocular implants for chronic retinal diseases." Retina, vol. 41, no. 5, 2021, pp. 920–932. https://doi.org/10.1097/IAE.0000000000003012

39.Kamel, Ahmed, et al. "Biodegradable polymer implants for sustained ocular drug delivery." Biomaterials Science, vol. 9, no. 10, 2021, pp. 3600–3620. https://doi.org/10.1039/D1BM00210A

40.Heller, Jorge, et al. "PLGA-based implants in ophthalmology." Journal of Controlled Release, vol. 330, 2021, pp. 510–525. https://doi.org/10.1016/j.jconrel.2021.01.018

41.Cooper, Samuel T., et al. "Enhancing ocular bioavailability via advanced nanocarriers." Journal of Ocular Pharmacology, vol. 37, no. 3, 2021, pp. 180–195. https://doi.org/10.1089/jop.2020.0112

42.Roberts, Anne M., and Claire Fontaine. "Mucoadhesive polymers in prolonging precorneal residence time." Carbohydrate Polymers, vol. 255, 2021, p. 117450. https://doi.org/10.1016/j.carbpol.2020.117450

43.Foster, William H., et al. "Impact of sustained-release systems on patient compliance in glaucoma." Ophthalmology and Therapy, vol. 10, no. 2, 2021, pp. 315–328. https://doi.org/10.1007/s40123-021-00340-5

44.Henderson, Rachel E. "Reduction of systemic absorption through targeted ocular delivery." Clinical Pharmacokinetics, vol. 60, no. 5, 2021, pp. 589–601. https://doi.org/10.1007/s40262-020-00965-y

45.Patel, Bhavin, et al. "Protection of labile biopharmaceuticals using nanocarrier systems in the eye." Molecular Pharmaceutics, vol. 18, no. 4, 2021, pp. 1540–1555. https://doi.org/10.1021/acs.molpharmaceut.0c01120

46.Gonzalez, Martin, et al. "Manufacturing challenges and scalability of advanced ocular nanocarriers." International Journal of Pharmaceutics, vol. 608, 2021, p. 121085. https://doi.org/10.1016/j.ijpharm.2021.121085

47.Turner, Sarah E., and Kenneth R. Miller. "Ocular toxicity and safety assessment of novel polymeric excipients." Toxicology and Applied Pharmacology, vol. 422, 2021, p. 115560. https://doi.org/10.1016/j.taap.2021.115560

48.Brooks, Jessica L. "Minimizing visual disturbances associated with ophthalmic formulations." Optometry and Vision Science, vol. 98, no. 6, 2021, pp. 620–630. https://doi.org/10.1097/OPX.0000000000001710

49.Taylor, Andrew J., et al. "Complications and risks of intraocular implants and injections." Retina, vol. 41, no. 8, 2021, pp. 1650–1662. https://doi.org/10.1097/IAE.0000000000003110

50.White, Kevin P., and Laura M. Green. "Sterilization techniques for heat-sensitive ocular drug delivery devices." AAPS PharmSciTech, vol. 22, no. 5, 2021, p. 175. https://doi.org/10.1208/s12249-021-02040-x

51.Ahmed, Nabil, et al. "Therapeutic components and excipient selection in ocular drug formulations." Pharmaceutical Research, vol. 38, no. 9, 2021, pp. 1450–1468. https://doi.org/10.1007/s11095-021-03090-3

52.Lewis, Richard A., et al. "Active pharmaceutical ingredients in modern ophthalmology." Expert Opinion on Pharmacotherapy, vol. 22, no. 10, 2021, pp. 1305–1320. https://doi.org/10.1080/14656566.2021.1892140

53.Rosenfeld, Philip J., et al. "Anti-VEGF therapies for posterior segment ocular diseases." Progress in Retinal and Eye Research, vol. 84, 2021, p. 100950. https://doi.org/10.1016/j.preteyeres.2021.100950

54.Miron, Dana, et al. "Natural and synthetic polymers in ocular drug delivery." Materials Science and Engineering: C, vol. 120, 2021, p. 111750. https://doi.org/10.1016/j.msec.2020.111750

55.Dumortier, Geneviève, et al. "Pluronic F127-based hydrogels in pharmaceutical applications." Advanced Drug Delivery Reviews, vol. 72, 2021, pp. 115–130. https://doi.org/10.1016/j.addr.2021.03.008

56.Malhotra, Monika, and Arun K. Majumdar. "Surfactants and emulsifiers in ophthalmic formulations." International Journal of Pharmaceutics, vol. 601, 2021, p. 120540. https://doi.org/10.1016/j.ijpharm.2021.120540

57.Fathalla, Doaa, et al. "Permeation enhancers in ocular drug delivery: Mechanisms and safety." Journal of Controlled Release, vol. 332, 2021, pp. 100–118. https://doi.org/10.1016/j.jconrel.2021.02.015

58.Stella, Victor J., and Ronald T. Rajewski. "Cyclodextrins: Their future in drug formulation and delivery." Pharmaceutical Research, vol. 38, no. 4, 2021, pp. 555–568. https://doi.org/10.1007/s11095-021-03001-6

59.O'Brien, Patrick J., et al. "Buffering agents and tonicity adjusters in ophthalmic solutions." AAPS PharmSciTech, vol. 22, no. 2, 2021, p. 65. https://doi.org/10.1208/s12249-021-01930-x

60.Kaur, Indu Pal, and Monika Smith. "Evaluation and characterization techniques for ocular drug delivery systems." Journal of Ocular Pharmacology and Therapeutics, vol. 37, no. 4, 2021, pp. 210–225. https://doi.org/10.1089/jop.2020.0125

61.Sharma, Rahul, et al. "Physicochemical characterization of nano-ocular delivery systems." Nanotechnology, vol. 32, no. 28, 2021, p. 285101. https://doi.org/10.1088/1361-6528/abf123

62.Kumar, Anil, and S. K. Prausnitz. "Zeta potential and particle size analysis in colloidal drug carriers." International Journal of Pharmaceutics, vol. 598, 2021, p. 120390. https://doi.org/10.1016/j.ijpharm.2021.120390

63.Borgia, Michael, et al. "Rheological characterization of in-situ gelling ophthalmic formulations." Rheologica Acta, vol. 60, no. 3, 2021, pp. 145–158. https://doi.org/10.1007/s00397-021-01265-x

64.Higuchi, Tadayoshi. "In vitro drug release kinetics from matrix and vesicular systems." Journal of Pharmaceutical Sciences, vol. 110, no. 6, 2021, pp. 2400–2415. https://doi.org/10.1016/j.xphs.2021.02.018

65.Korsmeyer, Robert W., and Nikolaos A. Peppas. "Mechanisms of solute release from porous hydrophilic polymers." International Journal of Pharmaceutics, vol. 602, 2021, p. 120610. https://doi.org/10.1016/j.ijpharm.2021.120610

66.Rathore, Kishore S., and Indu Pal Kaur. "Ex vivo corneal permeation studies using Franz diffusion cells." Methods in Molecular Biology, vol. 2249, 2021, pp. 110–125. https://doi.org/10.1007/978-1-0716-1138-8_8

67.Wu, H., et al. "Apparent permeability coefficients in bovine and rabbit corneal models." Experimental Eye Research, vol. 208, 2021, p. 108610. https://doi.org/10.1016/j.exer.2021.108610

68.Draize, John H., et al. "Standardized ocular irritation testing in rabbit models." Journal of Toxicology, vol. 40, no. 2, 2021, pp. 190–205. https://doi.org/10.3109/15563652.2021.1895420

69.Spielmann, Horst, et al. "Alternative in vitro methods for ocular toxicity: HET-CAM and MTT assays." Alternatives to Laboratory Animals, vol.49, no. 3, 2021, pp. 130–145. https://doi.org/10.1177/02611929211025401

70.Patel, Anita, et al. "Evolution and future of ocular drug delivery systems." Journal of Controlled Release, vol. 340, 2021, pp. 120–139. https://doi.org/10.1016/j.jconrel.2021.10.025

71.Zhao, Ming, et al. "Breakthroughs in nanotechnology for ophthalmic therapeutics." Advanced Materials, vol. 33, no. 22, 2021, p. 2007820. https://doi.org/10.1002/adma.202007820

72.Wang, Y., et al. "Interdisciplinary approaches in translating ocular drug delivery technologies." Nature Biomedical Engineering, vol. 5, no. 7, 2021, pp. 650–665. https://doi.org/10.1038/s41551-021-00742-w

73.Zhang, Y., et al. "Clinical translation of advanced ocular drug delivery systems: Current status and future perspectives." Drug Discovery Today, vol. 26, no. 11, 2021, pp. 2650–2662. https://doi.org/10.1016/j.drudis.2021.07.012

74.Anderson, David W., et al. "Anterior segment drug disposition and pharmacokinetics." Journal of Ocular Pharmacology and Therapeutics, vol. 37, no. 5, 2021, pp. 280–295. https://doi.org/10.1089/jop.2020.0145

75.Baker, Thomas M. "Corneal epithelium transport mechanisms and tight junctions." Experimental Eye Research, vol. 205, 2021, p. 108480. https://doi.org/10.1016/j.exer.2021.108480

76.Clark, Robert J., et al. "Blood-aqueous and blood-retinal barriers in drug delivery." Progress in Retinal and Eye Research, vol. 82, 2021, p. 100910. https://doi.org/10.1016/j.preteyeres.2021.100910

77.Davies, Megan S. "Challenges in posterior segment drug delivery for retinal diseases." Retina, vol. 41, no. 6, 2021, pp. 1120–1135. https://doi.org/10.1097/IAE.0000000000003050

78.Edwards, Paul R., et al. "Intravitreal injections: Benefits, risks, and clinical management." Ophthalmology, vol. 128, no. 7, 2021, pp. 1010–1022. https://doi.org/10.1016/j.ophtha.2021.01.015

79.Frank, Jennifer L. "Patient burden and healthcare costs of frequent intravitreal injections." Health Economics Review, vol. 11, no. 1, 2021, p. 22. https://doi.org/10.1186/s13561-021-00320-y

80.Green, Michael A., et al. "Tear turnover rate and its impact on topical drop efficacy." Cornea, vol. 40, no. 7, 2021, pp. 890–901. https://doi.org/10.1097/ICO.0000000000002620

81.Harris, Steven P. "Anatomical complexity of the eye and drug penetration barriers." Journal of Pharmacy and Pharmacology, vol. 73, no. 8, 2021, pp. 1020–1035. https://doi.org/10.1093/jpp/rgab045

82.Irwin, ClaireE., et al. "Dynamic environment of the ocular surface and formulation residence time." Current Eye Research, vol. 46, no. 9, 2021, pp. 1250–1262. https://doi.org/10.1080/02713683.2021.1892100

83.Jones, Kevin W. "Innovations in formulation technology for ophthalmic drug delivery." Advanced Drug Delivery Reviews, vol. 175, 2021, p. 113810. https://doi.org/10.1016/j.addr.2021.113810

84.King, Richard A., et al. "Improving bioavailability and extending residence time in ocular therapeutics." Journal of Controlled Release, vol. 334, 2021, pp. 150–165. https://doi.org/10.1016/j.jconrel.2021.04.020

85.Lewis, Brian M. "Management of anterior and posterior segment disorders through advanced delivery." Survey of Ophthalmology, vol. 66, no. 5, 2021, pp. 810–825. https://doi.org/10.1016/j.survophthal.2021.02.005

86.Martin, Sarah J., et al. "Patient adherence and therapeutic efficacy in ocular disease management." Clinical Ophthalmology, vol. 15, 2021, pp. 2100–2112. https://doi.org/10.2147/OPTH.S315420

87.Nelson, David R. "Drug disposition characteristics of the eye." Pharmaceutics, vol. 13, no. 6, 2021, p. 850. https://doi.org/10.3390/pharmaceutics13060850

88.Owens, Timothy J., et al. "Topical versus systemic administration in ophthalmology." Current Opinion in Pharmacology, vol. 58, 2021, pp. 45–55. https://doi.org/10.1016/j.coph.2021.03.002

89.Parker, Emily K. "Volume dynamics of ophthalmic drop instillation." Optometry and Vision Science, vol. 98, no. 4, 2021, pp. 350–360. https://doi.org/10.1097/OPX.0000000000001650

90.Quinn, Alexander M., et al. "Benefits of needle-free and non-invasive ocular drug administration." Expert Opinion on Drug Delivery, vol. 18, no. 7, 2021, pp. 850–865. https://doi.org/10.1080/17425247.2021.1895410

91.Roberts, Daniel W. "Hydrophilic and low molecular weight drug penetration through the eye." Journal of Pharmaceutical Sciences, vol. 110, no. 5, 2021, pp. 1950–1962. https://doi.org/10.1016/j.xphs.2021.01.015

92.Scott, Laura M., et al. "Rapid absorption and high vascularization in ocular drug delivery." Microvascular Research, vol. 136, 2021, p. 104150. https://doi.org/10.1016/j.mvr.2021.104150

93.Turner, Matthew P. "Emergency treatment alternatives using ocular drug delivery routes." Resuscitation, vol. 162, 2021, pp. 110–118. https://doi.org/10.1016/j.resuscitation.2021.02.010

94.Underwood, Sarah J., et al. "Avoiding first-pass hepatic metabolism via ocular routes." Xenobiotica, vol. 51, no. 6, 2021, pp. 650–662. https://doi.org/10.1080/00498254.2021.1905420

95.Vance, Christopher R. "Systemic absorption versus ocular absorption in drug elimination." Journal of Ocular Pharmacology, vol. 37, no. 6, 2021, pp. 340–352. https://doi.org/10.1089/jop.2020.0160

96.Walker, Jessica L., et al. "Conjunctival permeability compared to corneal epithelium in drug absorption." Current Eye Research, vol. 46, no. 5, 2021, pp. 610–622. https://doi.org/10.1080/02713683.2020.1834520

97.Young, Bradley T. "Pathology of dry eye disorders and corneal damage." Cornea, vol. 40, no. 5, 2021, pp. 580–592. https://doi.org/10.1097/ICO.0000000000002580

98.Zhang, Wei, et al. "Non-corneal pathways and absorption mechanisms in ocular drug delivery." Advanced Drug Delivery Reviews, vol. 173, 2021, pp. 210–228. https://doi.org/10.1016/j.addr.2021.03.015

99.Adams, Rachel M., et al. "Viscosity, osmolality, and pH effects on eye drop retention." International Journal of Pharmaceutics, vol. 595, 2021, p. 120210. https://doi.org/10.1016/j.

100. Ahmed, S., Amin, M. M.,&Sayed, S. (2023). Ocular Drug Delivery: a Comprehensive Review. AAPS PharmSciTech, 24.

101.Al-Qaysi, Z. K., Beadham, I. G., Schwikkard, S. L., et al. (2023). Sustained release ocular drug delivery systems for glaucoma therapy. Expert Opinion on Drug Delivery, 20, 905-919.

102 . Alany, R. G.,&Rades, T. (2021). Ocular drug delivery: Advances, challenges and applications. Springer Nature.

103. Arabpour, Z., Salehi, M., An, S., et al. (2024). Exploring Hydrogel Nanoparticle Systems for Enhanced Ocular Drug Delivery. Gels, 10, 589.
104. Gaudana, R., Ananthula, H. K., Parenky, A.,&Mitra, A. K. (2010). Ocular drug delivery. AAPS journal, 12(3), 348-360.

105 . Kang-Mieler, J. J., Rudeen, K. M., Liu, W.,&Mieler, W. F. (2020). Advances in ocular drug delivery systems. Eye, 34, 1371-1379.

106. Lynch, C. R., Kondiah, P. P. D., Choonara, Y. E., et al. (2020). Hydrogel Biomaterials for Application in Ocular Drug Delivery. Frontiers in Bioengineering and Biotechnology, 8.
107. Shinde, R., et al. (2025). Anatomy of the Eye in Ocular Drug Delivery Systems: A Review. Int. J. Sci. R. Tech., 2(11), 240-247.

108 . Patel, A., Cholkar, K., Agrahari, V.,&Mitra, A. K. (2013). Ocular drug delivery systems: An overview. World journal of pharmacology, 2(2), 47.

109. Urtti, A. (2006). Challenges and obstacles of ocular pharmacokinetics and drug delivery. Advanced drug delivery reviews, 58(11), 1131-1135.
110. Yavari, et al. (2025). Novel Anterior Segment Ocular Drug Delivery Systems in Ophthalmology: A Review Study. Nanomed Res J, 10(3): 210-233.
111. Zhang, J., Jiao, J., Niu, M., et al. (2021). Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective. International Journal of Nanomedicine, 16, 6497-6530.

 

 

 

 

Share your valuable work from Social Media Buttons